Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	actin binding	NF2 SYN1 DAG1 EZR WASL	3.79e-05	479	17	5	GO:0003779
GeneOntologyBiologicalProcess	positive regulation of early endosome to late endosome transport	NF2 EZR	2.29e-05	9	17	2	GO:2000643
GeneOntologyBiologicalProcess	regulation of protein localization to early endosome	NF2 EZR	2.87e-05	10	17	2	GO:1902965
GeneOntologyBiologicalProcess	positive regulation of protein localization to early endosome	NF2 EZR	2.87e-05	10	17	2	GO:1902966
GeneOntologyBiologicalProcess	positive regulation of protein localization to endosome	NF2 EZR	5.78e-05	14	17	2	GO:1905668
GeneOntologyBiologicalProcess	regulation of protein localization to endosome	NF2 EZR	6.67e-05	15	17	2	GO:1905666
GeneOntologyBiologicalProcess	protein localization to early endosome	NF2 EZR	7.62e-05	16	17	2	GO:1902946
GeneOntologyBiologicalProcess	regulation of early endosome to late endosome transport	NF2 EZR	1.20e-04	20	17	2	GO:2000641
GeneOntologyBiologicalProcess	regulation of cell shape	NF2 DAG1 EZR	2.82e-04	159	17	3	GO:0008360
GeneOntologyBiologicalProcess	postsynaptic actin cytoskeleton organization	EZR WASL	2.93e-04	31	17	2	GO:0098974
GeneOntologyBiologicalProcess	protein localization to endosome	NF2 EZR	3.33e-04	33	17	2	GO:0036010
GeneOntologyBiologicalProcess	postsynaptic cytoskeleton organization	EZR WASL	3.74e-04	35	17	2	GO:0099188
GeneOntologyBiologicalProcess	negative regulation of MAPK cascade	NF2 DAG1 EZR	5.61e-04	201	17	3	GO:0043409
GeneOntologyBiologicalProcess	gastrulation	ARID1A NF2 DAG1	6.55e-04	212	17	3	GO:0007369
GeneOntologyBiologicalProcess	protein kinase A signaling	EZR FBN1	7.05e-04	48	17	2	GO:0010737
GeneOntologyBiologicalProcess	early endosome to late endosome transport	NF2 EZR	7.65e-04	50	17	2	GO:0045022
GeneOntologyBiologicalProcess	positive regulation of stem cell population maintenance	ARID1A BICRA	7.96e-04	51	17	2	GO:1902459
GeneOntologyBiologicalProcess	cell junction organization	NF2 SYN1 DAG1 EZR WASL	8.94e-04	974	17	5	GO:0034330
GeneOntologyBiologicalProcess	vesicle-mediated transport between endosomal compartments	NF2 EZR	9.59e-04	56	17	2	GO:0098927
GeneOntologyCellularComponent	lamellipodium	NF2 DAG1 WASL APBB1IP	3.04e-05	230	17	4	GO:0030027
GeneOntologyCellularComponent	cell leading edge	NF2 DAG1 EZR WASL APBB1IP	3.74e-05	500	17	5	GO:0031252
GeneOntologyCellularComponent	filopodium	NF2 DAG1 EZR	1.27e-04	123	17	3	GO:0030175
GeneOntologyCellularComponent	cortical cytoskeleton	NF2 EZR WASL	1.47e-04	129	17	3	GO:0030863
GeneOntologyCellularComponent	SWI/SNF complex	ARID1A BICRA	2.67e-04	30	17	2	GO:0016514
GeneOntologyCellularComponent	adherens junction	NF2 DAG1 EZR	6.30e-04	212	17	3	GO:0005912
GeneOntologyCellularComponent	actin-based cell projection	NF2 DAG1 EZR	1.38e-03	278	17	3	GO:0098858
GeneOntologyCellularComponent	cortical actin cytoskeleton	NF2 WASL	2.55e-03	93	17	2	GO:0030864
GeneOntologyCellularComponent	SWI/SNF superfamily-type complex	ARID1A BICRA	2.71e-03	96	17	2	GO:0070603
GeneOntologyCellularComponent	cell cortex	NF2 EZR WASL	3.13e-03	371	17	3	GO:0005938
GeneOntologyCellularComponent	ruffle membrane	NF2 EZR	3.42e-03	108	17	2	GO:0032587
GeneOntologyCellularComponent	basement membrane	DAG1 FBN1	4.34e-03	122	17	2	GO:0005604
GeneOntologyCellularComponent	focal adhesion	DAG1 EZR APBB1IP	4.77e-03	431	17	3	GO:0005925
GeneOntologyCellularComponent	ATPase complex	ARID1A BICRA	4.84e-03	129	17	2	GO:1904949
GeneOntologyCellularComponent	cell-substrate junction	DAG1 EZR APBB1IP	5.15e-03	443	17	3	GO:0030055
GeneOntologyCellularComponent	plasma membrane raft	DAG1 EZR	6.23e-03	147	17	2	GO:0044853
GeneOntologyCellularComponent	anchoring junction	NF2 DAG1 EZR APBB1IP	6.90e-03	976	17	4	GO:0070161
MousePheno	failure to gastrulate	ARID1A NF2 DAG1 YLPM1	6.34e-06	119	15	4	MP:0001696
MousePheno	absent mesoderm	ARID1A NF2 DAG1	4.60e-05	67	15	3	MP:0001683
MousePheno	abnormal gastrulation	ARID1A NF2 DAG1 WASL YLPM1	9.45e-05	469	15	5	MP:0001695
MousePheno	absent extraembryonic ectoderm	NF2 DAG1	1.12e-04	15	15	2	MP:0002583
MousePheno	abnormal extraembryonic tissue morphology	ARID1A NF2 DAG1 WASL PEG10 FBN1	2.22e-04	908	15	6	MP:0002086
MousePheno	abnormal developmental patterning	ARID1A NF2 DAG1 WASL YLPM1	2.50e-04	577	15	5	MP:0002084
MousePheno	abnormal embryo development	ARID1A NF2 DAG1 BICRA WASL PEG10 YLPM1	2.71e-04	1370	15	7	MP:0001672
MousePheno	abnormal mesoderm morphology	ARID1A NF2 DAG1	3.08e-04	127	15	3	MP:0014141
MousePheno	absent heartbeat	ARID1A WASL	3.18e-04	25	15	2	MP:0004086
MousePheno	decreased embryo size	ARID1A DAG1 BICRA WASL YLPM1	4.64e-04	659	15	5	MP:0001698
MousePheno	abnormal extraembryonic ectoderm morphology	NF2 DAG1	4.91e-04	31	15	2	MP:0010736
MousePheno	abnormal germ layer morphology	ARID1A NF2 DAG1	6.16e-04	161	15	3	MP:0014138
MousePheno	abnormal embryonic tissue morphology	ARID1A NF2 DAG1 WASL NR5A1 YLPM1	6.81e-04	1116	15	6	MP:0002085
Domain	ERM_C_dom	NF2 EZR	4.67e-06	4	17	2	IPR011259
Domain	ERM	NF2 EZR	4.67e-06	4	17	2	IPR011174
Domain	ERM	NF2 EZR	4.67e-06	4	17	2	PF00769
Domain	Moesin_tail	NF2 EZR	1.63e-05	7	17	2	IPR008954
Domain	Ez/rad/moesin-like	NF2 EZR	1.62e-04	21	17	2	IPR000798
Domain	FERM_CS	NF2 EZR	2.13e-04	24	17	2	IPR019747
Domain	FERM_C	NF2 EZR	2.50e-04	26	17	2	PF09380
Domain	FERM_C	NF2 EZR	2.70e-04	27	17	2	SM01196
Domain	FERM_PH-like_C	NF2 EZR	2.70e-04	27	17	2	IPR018980
Domain	-	NF2 EZR WASL APBB1IP	3.63e-04	391	17	4	2.30.29.30
Domain	FERM_N	NF2 EZR	4.05e-04	33	17	2	IPR018979
Domain	FERM_N	NF2 EZR	4.05e-04	33	17	2	PF09379
Domain	PH_dom-like	NF2 EZR WASL APBB1IP	5.02e-04	426	17	4	IPR011993
Domain	Ubiquitin-rel_dom	NF2 EZR APBB1IP	5.78e-04	184	17	3	IPR029071
Domain	FERM_M	NF2 EZR	7.88e-04	46	17	2	PF00373
Domain	FERM_domain	NF2 EZR	8.94e-04	49	17	2	IPR000299
Domain	FERM_central	NF2 EZR	8.94e-04	49	17	2	IPR019748
Domain	-	NF2 EZR	8.94e-04	49	17	2	1.20.80.10
Domain	FERM_1	NF2 EZR	9.31e-04	50	17	2	PS00660
Domain	FERM_2	NF2 EZR	9.31e-04	50	17	2	PS00661
Domain	B41	NF2 EZR	9.31e-04	50	17	2	SM00295
Domain	FERM/acyl-CoA-bd_prot_3-hlx	NF2 EZR	9.31e-04	50	17	2	IPR014352
Domain	FERM_3	NF2 EZR	9.31e-04	50	17	2	PS50057
Domain	Band_41_domain	NF2 EZR	9.31e-04	50	17	2	IPR019749
Pubmed	WW domains provide a platform for the assembly of multiprotein networks.	ARID1A WASL APBB1IP SCAF4 YLPM1	9.45e-09	154	17	5	16055720
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ARID1A NF2 EZR PRRC2A WASL PEG10 FBN1 YLPM1	6.14e-08	1285	17	8	35914814
Pubmed	Nuclear actin interactome analysis links actin to KAT14 histone acetyl transferase and mRNA splicing.	ARID1A EZR WASL SCAF4 SON YLPM1	9.95e-08	506	17	6	30890647
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	ARID1A NF2 EZR PRRC2A SCAF4 YLPM1	1.61e-07	549	17	6	38280479
Pubmed	Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin.	NF2 EZR	2.25e-07	2	17	2	10036239
Pubmed	The expression and phosphorylation of ezrin and merlin in human pancreatic cancer.	NF2 EZR	2.25e-07	2	17	2	24728215
Pubmed	NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin.	NF2 EZR	2.25e-07	2	17	2	26483553
Pubmed	Merlin/ERM proteins establish cortical asymmetry and centrosome position.	NF2 EZR	2.25e-07	2	17	2	23249734
Pubmed	Nuclear import of β-dystroglycan is facilitated by ezrin-mediated cytoskeleton reorganization.	DAG1 EZR	2.25e-07	2	17	2	24599031
Pubmed	Characterization of the NF2 protein merlin and the ERM protein ezrin in human, rat, and mouse central nervous system.	NF2 EZR	2.25e-07	2	17	2	15797715
Pubmed	Ezrin and moesin are required for efficient T cell adhesion and homing to lymphoid organs.	NF2 EZR	2.25e-07	2	17	2	23468835
Pubmed	The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function.	NF2 WASL	2.25e-07	2	17	2	15699051
Pubmed	Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma.	NF2 EZR	2.25e-07	2	17	2	20156804
Pubmed	Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization.	NF2 EZR	6.74e-07	3	17	2	14981079
Pubmed	Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors.	NF2 EZR	6.74e-07	3	17	2	21971708
Pubmed	Two Sides of the Coin: Ezrin/Radixin/Moesin and Merlin Control Membrane Structure and Contact Inhibition.	NF2 EZR	1.35e-06	4	17	2	31018575
Pubmed	Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout.	NF2 EZR	1.35e-06	4	17	2	9890997
Pubmed	The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts.	EZR PRRC2A PEG10 SCAF4 SON YLPM1	1.52e-06	807	17	6	22681889
Pubmed	The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.	ARID1A NF2	2.25e-06	5	17	2	30401838
Pubmed	Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation.	NF2 EZR	2.25e-06	5	17	2	17891137
Pubmed	Human transcription factor protein interaction networks.	ARID1A PRRC2A BICRA PEG10 FBN1 SCAF4 YLPM1	2.64e-06	1429	17	7	35140242
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	NF2 EZR WASL PEG10 SON	3.14e-06	497	17	5	23414517
Pubmed	Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.	PRRC2A WASL SCAF4 YLPM1	3.48e-06	220	17	4	24550385
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	ARID1A PRRC2A BICRA SCAF4 SON YLPM1	4.01e-06	954	17	6	36373674
Pubmed	NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands.	NF2 EZR	4.72e-06	7	17	2	17242191
Pubmed	Structural diversity of band 4.1 superfamily members.	NF2 EZR	6.29e-06	8	17	2	7983158
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	ARID1A PRRC2A MCM3AP SON YLPM1	1.18e-05	653	17	5	22586326
Pubmed	Disruption of murine Adamtsl4 results in zonular fiber detachment from the lens and in retinal pigment epithelium dedifferentiation.	EZR FBN1	1.48e-05	12	17	2	26405179
Pubmed	Alpha6beta4 integrin and dystroglycan cooperate to stabilize the myelin sheath.	DAG1 EZR	1.48e-05	12	17	2	18579745
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	DAG1 BICRA WASL NR5A1	1.70e-05	329	17	4	17474147
Pubmed	The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.	ARID1A NF2 PRRC2A SON	1.76e-05	332	17	4	37433992
Pubmed	Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS.	DAG1 PRRC2A WASL	1.92e-05	108	17	3	19531213
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	NF2 PRRC2A WASL SON YLPM1	1.94e-05	724	17	5	36232890
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	ARID1A PEG10 MCM3AP YLPM1	1.95e-05	341	17	4	32971831
Pubmed	Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks.	SYN1 WASL YLPM1	2.08e-05	111	17	3	22558309
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	PRRC2A PEG10 MCM3AP SCAF4 SON YLPM1	3.16e-05	1371	17	6	36244648
Pubmed	Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling.	PRRC2A BICRA SON YLPM1	3.61e-05	399	17	4	35987950
Pubmed	A gene expression map of human chromosome 21 orthologues in the mouse.	MCM3AP SCAF4 SON	5.97e-05	158	17	3	12466855
Pubmed	Human chromosome 21 gene expression atlas in the mouse.	MCM3AP SCAF4 SON	6.55e-05	163	17	3	12466854
Pubmed	The transcription factor GATA4 is required for follicular development and normal ovarian function.	SYN1 NR5A1	7.26e-05	26	17	2	23769843
Pubmed	Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.	ARID1A BICRA	7.84e-05	27	17	2	29374058
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	DAG1 MCM3AP YLPM1	8.79e-05	180	17	3	35198878
Pubmed	An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency.	ARID1A BICRA	9.06e-05	29	17	2	19279220
Pubmed	Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes.	APBB1IP YLPM1	1.04e-04	31	17	2	19041431
Pubmed	Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.	ARID1A DAG1 PRRC2A SCAF4	1.13e-04	536	17	4	15840001
Pubmed	Exchangeable gene trap using the Cre/mutated lox system.	ARID1A DAG1 PRRC2A SCAF4	1.15e-04	538	17	4	10512203
Pubmed	Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.	EZR BICRA PEG10 MAN1B1 MCM3AP	1.19e-04	1061	17	5	33845483
Pubmed	RSPO-LGR4 functions via IQGAP1 to potentiate Wnt signaling.	PRRC2A WASL YLPM1	1.24e-04	202	17	3	24639526
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	ARID1A EZR SCAF4 SON YLPM1	1.31e-04	1082	17	5	38697112
Pubmed	Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors.	DAG1 EZR	1.40e-04	36	17	2	25715395
Pubmed	Ovarian development in mice requires the GATA4-FOG2 transcription complex.	SYN1 NR5A1	1.40e-04	36	17	2	18927154
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	ARID1A EZR PRRC2A BICRA SCAF4	1.43e-04	1103	17	5	34189442
Pubmed	TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.	ARID1A SON YLPM1	1.59e-04	220	17	3	35785414
Pubmed	Functional proteomics mapping of a human signaling pathway.	PEG10 MCM3AP SON YLPM1	1.65e-04	591	17	4	15231748
Pubmed	A protein interaction landscape of breast cancer.	ARID1A DAG1 BICRA SCAF4	2.16e-04	634	17	4	34591612
Pubmed	Congenital Diaphragmatic Hernia Overview	ARID1A FBN1	2.30e-04	46	17	2	20301533
Pubmed	Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development.	EZR WASL	2.30e-04	46	17	2	23555292
Pubmed	The DNA sequence of human chromosome 21.	MCM3AP SCAF4 SON	2.54e-04	258	17	3	10830953
Pubmed	ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.	NF2 FBN1	3.53e-04	57	17	2	23788249
Pubmed	Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.	ARID1A DAG1 EZR SON YLPM1	3.88e-04	1367	17	5	32687490
Pubmed	A protein-protein interaction map of the TNF-induced NF-κB signal transduction pathway.	NF2 PRRC2A YLPM1	4.03e-04	302	17	3	30561431
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	PRRC2A SCAF4 SON YLPM1	4.60e-04	774	17	4	15302935
Interaction	ACTC1 interactions	ARID1A EZR BICRA WASL SCAF4 SON YLPM1	8.02e-07	694	17	7	int:ACTC1
Interaction	PTK2 interactions	NF2 DAG1 EZR WASL APBB1IP	4.79e-06	315	17	5	int:PTK2
Interaction	ITSN2 interactions	SYN1 EZR WASL YLPM1	6.01e-06	147	17	4	int:ITSN2
Interaction	MEN1 interactions	ARID1A PRRC2A PEG10 NR5A1 MCM3AP SON YLPM1	1.10e-05	1029	17	7	int:MEN1
Interaction	SSRP1 interactions	ARID1A NF2 PRRC2A SCAF4 SON YLPM1	1.35e-05	685	17	6	int:SSRP1
Interaction	YAP1 interactions	ARID1A NF2 EZR PRRC2A WASL SCAF4 YLPM1	1.65e-05	1095	17	7	int:YAP1
Interaction	PRPF40A interactions	WASL APBB1IP SCAF4 SON YLPM1	2.58e-05	446	17	5	int:PRPF40A
Interaction	GRB2 interactions	NF2 SYN1 DAG1 PRRC2A WASL YLPM1	3.40e-05	806	17	6	int:GRB2
Interaction	PSPC1 interactions	NF2 PRRC2A PEG10 SON YLPM1	5.13e-05	515	17	5	int:PSPC1
Interaction	PRMT2 interactions	PRRC2A WASL YLPM1	5.79e-05	91	17	3	int:PRMT2
Interaction	NCK2 interactions	PRRC2A WASL NR5A1 YLPM1	5.82e-05	262	17	4	int:NCK2
Interaction	SMARCD3 interactions	ARID1A BICRA NR5A1	9.37e-05	107	17	3	int:SMARCD3
Interaction	PRX interactions	DAG1 EZR	1.02e-04	18	17	2	int:PRX
Interaction	CYFIP1 interactions	SYN1 EZR APBB1IP YLPM1	1.02e-04	303	17	4	int:CYFIP1
Interaction	SP7 interactions	ARID1A BICRA SCAF4 YLPM1	1.03e-04	304	17	4	int:SP7
Interaction	SMC5 interactions	ARID1A PRRC2A BICRA SCAF4 SON YLPM1	1.13e-04	1000	17	6	int:SMC5
Interaction	WWOX interactions	EZR PRRC2A WASL SCAF4 YLPM1	1.30e-04	627	17	5	int:WWOX
Interaction	MC1R interactions	NF2 EZR	1.53e-04	22	17	2	int:MC1R
Interaction	BMI1 interactions	EZR PRRC2A MAN1B1 SON YLPM1	1.64e-04	659	17	5	int:BMI1
Interaction	LAMA2 interactions	DAG1 FBN1	1.68e-04	23	17	2	int:LAMA2
Interaction	TOP1 interactions	ARID1A NF2 SCAF4 SON YLPM1	2.12e-04	696	17	5	int:TOP1
Interaction	TLE3 interactions	ARID1A MCM3AP SCAF4 SON	2.34e-04	376	17	4	int:TLE3
Interaction	WASF2 interactions	EZR WASL APBB1IP	2.35e-04	146	17	3	int:WASF2
Interaction	MEX3A interactions	ARID1A NF2 PRRC2A SON	2.54e-04	384	17	4	int:MEX3A
Interaction	ARID2 interactions	ARID1A NF2 BICRA	2.70e-04	153	17	3	int:ARID2
Interaction	SIRT7 interactions	ARID1A PRRC2A MCM3AP SON YLPM1	2.89e-04	744	17	5	int:SIRT7
Interaction	GATA4 interactions	ARID1A NR5A1 SON YLPM1	3.29e-04	411	17	4	int:GATA4
Interaction	WWTR1 interactions	ARID1A NF2 EZR PRRC2A	3.63e-04	422	17	4	int:WWTR1
Interaction	PNRC2 interactions	NF2 NR5A1	3.92e-04	35	17	2	int:PNRC2
Interaction	PACSIN2 interactions	EZR WASL APBB1IP	4.71e-04	185	17	3	int:PACSIN2
Interaction	GATA3 interactions	ARID1A PEG10 SCAF4	4.86e-04	187	17	3	int:GATA3
Interaction	PRM2 interactions	PRRC2A SCAF4	4.87e-04	39	17	2	int:PRM2
Interaction	WWP2 interactions	ARID1A NF2 DAG1 PRRC2A YLPM1	5.06e-04	840	17	5	int:WWP2
Interaction	HDLBP interactions	PRRC2A PEG10 MCM3AP SCAF4 YLPM1	5.49e-04	855	17	5	int:HDLBP
Interaction	APBB1 interactions	EZR WASL YLPM1	5.49e-04	195	17	3	int:APBB1
Interaction	NXF1 interactions	ARID1A NF2 PEG10 MCM3AP SON YLPM1	5.70e-04	1345	17	6	int:NXF1
Interaction	SNRPA interactions	PEG10 SCAF4 SON YLPM1	6.00e-04	482	17	4	int:SNRPA
Interaction	CLIP4 interactions	PEG10 SON	7.08e-04	47	17	2	int:CLIP4
Interaction	EP300 interactions	ARID1A MAN1B1 MCM3AP SCAF4 SON YLPM1	7.09e-04	1401	17	6	int:EP300
Interaction	ERG interactions	ARID1A SYN1 BICRA	8.11e-04	223	17	3	int:ERG
Interaction	CPSF6 interactions	NF2 SCAF4 SON YLPM1	8.33e-04	526	17	4	int:CPSF6
Interaction	EED interactions	ARID1A EZR MAN1B1 SCAF4 SON YLPM1	8.35e-04	1445	17	6	int:EED
Interaction	GAGE5 interactions	PRRC2A SCAF4	8.66e-04	52	17	2	int:GAGE5
Interaction	CLEC3A interactions	PRRC2A SCAF4	8.66e-04	52	17	2	int:CLEC3A
Interaction	TNIP2 interactions	NF2 DAG1 PRRC2A SCAF4 YLPM1	8.95e-04	952	17	5	int:TNIP2
Interaction	UQCR11 interactions	PRRC2A YLPM1	9.00e-04	53	17	2	int:UQCR11
Interaction	SAA1 interactions	PRRC2A YLPM1	9.34e-04	54	17	2	int:SAA1
Interaction	CFAP141 interactions	PRRC2A SCAF4	9.69e-04	55	17	2	int:CFAP141
Interaction	CDK5 interactions	NF2 SYN1 EZR	1.03e-03	242	17	3	int:CDK5
Interaction	SFPQ interactions	PRRC2A PEG10 SON YLPM1	1.07e-03	563	17	4	int:SFPQ
Interaction	CORO7 interactions	DAG1 WASL	1.11e-03	59	17	2	int:CORO7
Interaction	PACSIN1 interactions	WASL APBB1IP	1.15e-03	60	17	2	int:PACSIN1
Interaction	WWP1 interactions	DAG1 EZR WASL	1.26e-03	260	17	3	int:WWP1
Cytoband	Ensembl 112 genes in cytogenetic band chr21q22	MCM3AP SCAF4 SON	3.43e-04	377	17	3	chr21q22
GeneFamily	Zinc fingers MYND-type\|A-kinase anchoring proteins	NF2 EZR	1.62e-04	29	12	2	396
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	NF2 EZR	4.86e-04	50	12	2	1293
CoexpressionAtlas	DevelopingGonad_e18.5_testes_emap-11164_top-relative-expression-ranked_500	ARID1A DAG1 PRRC2A NR5A1 FBN1 SON	5.31e-07	412	17	6	gudmap_developingGonad_e18.5_testes_500
CoexpressionAtlas	DevelopingGonad_e12.5_testes_emap-29069_top-relative-expression-ranked_500	ARID1A DAG1 PRRC2A NR5A1 SON	1.28e-05	406	17	5	gudmap_developingGonad_e12.5_testes_500
CoexpressionAtlas	DevelopingGonad_P2_testes_emap-30171_top-relative-expression-ranked_500	ARID1A DAG1 PRRC2A NR5A1 FBN1	1.31e-05	408	17	5	gudmap_developingGonad_P2_testes_500
CoexpressionAtlas	DevelopingGonad_e16.5_testes_emap-8444_top-relative-expression-ranked_500	ARID1A PRRC2A NR5A1 FBN1 SON	1.32e-05	409	17	5	gudmap_developingGonad_e16.5_testes_500
CoexpressionAtlas	DevelopingGonad_e14.5_ testes_emap-6710_top-relative-expression-ranked_500	ARID1A PRRC2A NR5A1 FBN1 SON	1.35e-05	411	17	5	gudmap_developingGonad_e14.5_ testes_500
CoexpressionAtlas	DevelopingGonad_e18.5_testes_emap-11164_top-relative-expression-ranked_1000	ARID1A DAG1 PRRC2A NR5A1 FBN1 SON	2.68e-05	814	17	6	gudmap_developingGonad_e18.5_testes_1000
CoexpressionAtlas	DevelopingGonad_e16.5_testes_emap-8444_top-relative-expression-ranked_1000	ARID1A DAG1 PRRC2A NR5A1 FBN1 SON	2.78e-05	819	17	6	gudmap_developingGonad_e16.5_testes_1000
CoexpressionAtlas	DevelopingGonad_P2_testes_emap-30171_top-relative-expression-ranked_1000	ARID1A DAG1 PRRC2A NR5A1 FBN1 SON	2.78e-05	819	17	6	gudmap_developingGonad_P2_testes_1000
CoexpressionAtlas	DevelopingGonad_e14.5_ testes_emap-6710_top-relative-expression-ranked_1000	ARID1A DAG1 PRRC2A NR5A1 FBN1 SON	2.83e-05	822	17	6	gudmap_developingGonad_e14.5_ testes_1000
CoexpressionAtlas	DevelopingGonad_P2_testes_emap-30171_k-means-cluster#1_top-relative-expression-ranked_500	DAG1 NR5A1 FBN1	1.10e-04	119	17	3	gudmap_developingGonad_P2_testes_500_k1
CoexpressionAtlas	DevelopingGonad_e18.5_testes_emap-11164_k-means-cluster#1_top-relative-expression-ranked_500	ARID1A PRRC2A SON	1.78e-04	140	17	3	gudmap_developingGonad_e18.5_testes_500_k1
CoexpressionAtlas	DevelopingGonad_P2_ovary_emap-30224_k-means-cluster#1_top-relative-expression-ranked_1000	DAG1 WASL NR5A1	1.82e-04	141	17	3	gudmap_developingGonad_P2_ovary_1000_k1
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#4_top-relative-expression-ranked_1000	ARID1A DAG1 NR5A1	2.18e-04	150	17	3	gudmap_developingGonad_e12.5_ovary_k4_1000
CoexpressionAtlas	DevelopingGonad_e18.5_ovary_emap-12283_k-means-cluster#4_top-relative-expression-ranked_1000	DAG1 WASL NR5A1	2.64e-04	160	17	3	gudmap_developingGonad_e18.5_ovary_1000_k4
CoexpressionAtlas	DevelopingGonad_e16.5_testes_emap-8444_k-means-cluster#1_top-relative-expression-ranked_500	ARID1A PRRC2A SON	3.00e-04	167	17	3	gudmap_developingGonad_e16.5_testes_500_k1
CoexpressionAtlas	DevelopingGonad_e12.5_testes_emap-29069_top-relative-expression-ranked_1000	ARID1A DAG1 PRRC2A NR5A1 SON	3.54e-04	819	17	5	gudmap_developingGonad_e12.5_testes_1000
CoexpressionAtlas	DevelopingGonad_e11.5_testes and mesonephros_emap-3226_top-relative-expression-ranked_200	ARID1A PRRC2A SON	3.67e-04	179	17	3	gudmap_developingGonad_e11.5_testes and mesonephros_200
CoexpressionAtlas	DevelopingGonad_e14.5_ testes_emap-6710_k-means-cluster#2_top-relative-expression-ranked_1000	DAG1 NR5A1 FBN1	3.79e-04	181	17	3	gudmap_developingGonad_e14.5_ testes_1000_k2
CoexpressionAtlas	DevelopingGonad_e11.5_testes_emap-3226_top-relative-expression-ranked_200	ARID1A PRRC2A SON	3.79e-04	181	17	3	gudmap_developingGonad_e11.5_testes_200
CoexpressionAtlas	DevelopingGonad_e14.5_ testes_emap-6710_k-means-cluster#4_top-relative-expression-ranked_500	ARID1A PRRC2A SON	3.98e-04	184	17	3	gudmap_developingGonad_e14.5_ testes_500_k4
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#1_top-relative-expression-ranked_200	DAG1 NR5A1	5.10e-04	42	17	2	gudmap_developingGonad_e12.5_epididymis_k1_200
CoexpressionAtlas	DevelopingGonad_e16.5_testes_emap-8444_k-means-cluster#5_top-relative-expression-ranked_1000	DAG1 NR5A1 FBN1	6.18e-04	214	17	3	gudmap_developingGonad_e16.5_testes_1000_k5
CoexpressionAtlas	DevelopingGonad_e11.5_testes and mesonephros_emap-3226_k-means-cluster#2_top-relative-expression-ranked_100	ARID1A SON	7.23e-04	50	17	2	gudmap_developingGonad_e11.5_testes and mesonephros_k2_100
CoexpressionAtlas	dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k-means-cluster#2_top-relative-expression-ranked_500	PEG10 FBN1	8.42e-04	54	17	2	gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k2_500
CoexpressionAtlas	DevelopingGonad_e12.5_testes_emap-29069_k-means-cluster#4_top-relative-expression-ranked_500	ARID1A PRRC2A SON	8.73e-04	241	17	3	gudmap_developingGonad_e12.5_testes_k4_500
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#4_top-relative-expression-ranked_500	DAG1 NR5A1	1.04e-03	60	17	2	gudmap_developingGonad_e12.5_ovary_k4_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_2500_k-means-cluster#4	ARID1A SYN1 SON YLPM1	1.09e-03	595	17	4	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_2500_K4
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#1_top-relative-expression-ranked_1000	ARID1A DAG1 NR5A1	1.10e-03	261	17	3	gudmap_developingGonad_e12.5_epididymis_k1_1000
CoexpressionAtlas	kidney_P4_CapMesRenVes_Crym_k-means-cluster#1_top-relative-expression-ranked_1000	EZR FBN1	1.22e-03	65	17	2	gudmap_kidney_P4_CapMesRenVes_Crym_k1_1000
CoexpressionAtlas	DevelopingGonad_e12.5_testes_emap-29069_k-means-cluster#1_top-relative-expression-ranked_500	DAG1 NR5A1	1.93e-03	82	17	2	gudmap_developingGonad_e12.5_testes_k1_500
CoexpressionAtlas	DevelopingKidney_e15.5_Endothelial cells_emap-29965_k-means-cluster#5_top-relative-expression-ranked_1000	NF2 WASL	2.02e-03	84	17	2	gudmap_developingKidney_e15.5_Endothelial cells_1000_k5
ToppCell	PND03\|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	EZR APBB1IP SON	4.60e-05	187	17	3	b3fcb36d853adfdea7172c5591de06f027e50af3
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	ARID1A DAG1 SON	5.06e-05	193	17	3	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.2.4\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	EZR WASL PEG10	5.13e-05	194	17	3	54975e663ed4414b99b3c9a1aa6335613946470f
ToppCell	3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	EZR WASL PEG10	5.29e-05	196	17	3	a6a52cafd7c9994bc3d2f68b15a1491cd96ef908
ToppCell	10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_B_progenitor\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	EZR APBB1IP SON	5.37e-05	197	17	3	106b0f9a0425facc634feb7498c9ba2c55edfbf8
ToppCell	AT2_cells-Donor_07\|World / lung cells shred on cell class, cell subclass, sample id	EZR WASL PEG10	5.37e-05	197	17	3	c36513e893488c4299119d4fba6ef0fd72610ee6
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	EZR WASL PEG10 SON YLPM1	2.02e-07	187	17	5	4302_DN
Drug	Phenacetin [62-44-2]; Down 200; 22.4uM; HL60; HT_HG-U133A	NF2 EZR APBB1IP FBN1 MCM3AP	2.31e-07	192	17	5	2471_DN
Drug	Fluspirilen [1841-19-6]; Down 200; 8.4uM; PC3; HT_HG-U133A	ARID1A NF2 PRRC2A FBN1 SCAF4	2.49e-07	195	17	5	6662_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	EZR WASL PEG10 SON	8.12e-06	179	17	4	4585_DN
Drug	Homatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; PC3; HT_HG-U133A	EZR WASL PEG10 FBN1	1.07e-05	192	17	4	5058_DN
Drug	Y-27632; Up 200; 3uM; MCF7; HT_HG-U133A_EA	NF2 BICRA SCAF4 YLPM1	1.09e-05	193	17	4	948_UP
Drug	CP-690334-01 [459212-38-5]; Down 200; 10uM; MCF7; HT_HG-U133A	EZR WASL MCM3AP SON	1.09e-05	193	17	4	3906_DN
Drug	Nitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; MCF7; HT_HG-U133A	NF2 DAG1 BICRA FBN1	1.14e-05	195	17	4	4705_UP
Drug	Hesperetin [520-33-2]; Up 200; 13.2uM; MCF7; HT_HG-U133A	ARID1A NF2 DAG1 PRRC2A	1.16e-05	196	17	4	5350_UP
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; HL60; HT_HG-U133A	DAG1 BICRA PEG10 FBN1	1.16e-05	196	17	4	2515_UP
Drug	Tolazamide [1156-19-0]; Down 200; 12.8uM; HL60; HT_HG-U133A	EZR WASL APBB1IP MCM3AP	1.16e-05	196	17	4	2482_DN
Drug	Trichlorfon [52-68-6]; Down 200; 15.6uM; PC3; HT_HG-U133A	NF2 EZR BICRA YLPM1	1.21e-05	198	17	4	1797_DN
Drug	Naloxone hydrochloride [357-08-4]; Up 200; 11uM; HL60; HG-U133A	DAG1 BICRA MAN1B1 YLPM1	1.21e-05	198	17	4	2006_UP
Drug	Roxithromycin [80214-83-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A	PRRC2A BICRA SCAF4 YLPM1	1.23e-05	199	17	4	4778_DN
Drug	temozolomide	NF2 DAG1 BICRA	1.09e-04	127	17	3	CID000005394
Drug	decamethonium	NF2 PEG10	2.73e-04	33	17	2	CID000002968
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	DAG1 SON YLPM1	2.90e-04	177	17	3	4652_DN
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; PC3; HT_HG-U133A	EZR WASL SON	2.95e-04	178	17	3	3998_DN
Drug	Neostigmine bromide [114-80-7]; Down 200; 13.2uM; PC3; HT_HG-U133A	EZR PEG10 SON	3.46e-04	188	17	3	6735_DN
Drug	Lorglumide sodium salt [97964-56-2]; Down 200; 8.4uM; MCF7; HT_HG-U133A	NF2 DAG1 MCM3AP	3.51e-04	189	17	3	5254_DN
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; HL60; HG-U133A	ARID1A NF2 SCAF4	3.51e-04	189	17	3	2041_DN
Drug	0173570-0000 [211245-44-2]; Down 200; 10uM; PC3; HT_HG-U133A	EZR PEG10 YLPM1	3.51e-04	189	17	3	3690_DN
Drug	fluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A	NF2 MCM3AP SCAF4	3.62e-04	191	17	3	5234_DN
Drug	Fenbendazole [43210-67-9]; Down 200; 13.4uM; MCF7; HT_HG-U133A	NF2 DAG1 MCM3AP	3.62e-04	191	17	3	3888_DN
Drug	Harpagoside [19210-12-9]; Down 200; 8uM; MCF7; HT_HG-U133A	NF2 SCAF4 YLPM1	3.62e-04	191	17	3	4981_DN
Drug	Mefloquine hydrochloride [51773-92-3]; Down 200; 9.6uM; PC3; HT_HG-U133A	NF2 EZR PRRC2A	3.62e-04	191	17	3	2048_DN
Drug	Flunixin meglumine [42461-84-7]; Down 200; 8.2uM; PC3; HT_HG-U133A	EZR WASL YLPM1	3.62e-04	191	17	3	4273_DN
Drug	PF-00562151-00 [351320-12-2]; Down 200; 10uM; PC3; HT_HG-U133A	ARID1A NF2 DAG1	3.68e-04	192	17	3	5959_DN
Drug	Monobenzone [103-16-2]; Down 200; 20uM; HL60; HT_HG-U133A	ARID1A APBB1IP YLPM1	3.68e-04	192	17	3	3054_DN
Drug	WY-14643; Down 200; 100uM; PC3; HG-U133A	ARID1A BICRA FBN1	3.68e-04	192	17	3	464_DN
Drug	PHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A	NF2 PEG10 MCM3AP	3.74e-04	193	17	3	3773_DN
Drug	Decamethonium bromide [541-22-0]; Up 200; 9.6uM; HL60; HT_HG-U133A	NF2 WASL YLPM1	3.74e-04	193	17	3	2933_UP
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; HL60; HT_HG-U133A	NF2 EZR APBB1IP	3.74e-04	193	17	3	2477_DN
Drug	Ajmaline [4360-12-7]; Down 200; 12.2uM; HL60; HG-U133A	ARID1A DAG1 MCM3AP	3.74e-04	193	17	3	1749_DN
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; PC3; HT_HG-U133A	ARID1A BICRA MAN1B1	3.74e-04	193	17	3	6646_DN
Drug	Cyanocobalamin [68-19-9]; Down 200; 3uM; PC3; HT_HG-U133A	NF2 DAG1 MCM3AP	3.79e-04	194	17	3	4572_DN
Drug	Epivincamine [6835-99-0]; Up 200; 11.2uM; HL60; HG-U133A	PRRC2A WASL SCAF4	3.79e-04	194	17	3	1783_UP
Drug	Verapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; HL60; HG-U133A	ARID1A DAG1 SCAF4	3.79e-04	194	17	3	2009_DN
Drug	Pyrilamine maleate [59-33-6]; Down 200; 10uM; MCF7; HT_HG-U133A	NF2 PRRC2A MCM3AP	3.79e-04	194	17	3	3184_DN
Drug	Nifurtimox [23256-30-6]; Down 200; 14uM; MCF7; HT_HG-U133A	MCM3AP SCAF4 YLPM1	3.79e-04	194	17	3	4953_DN
Drug	Tridihexethyl chloride; Up 200; 11.4uM; MCF7; HT_HG-U133A	NF2 PRRC2A BICRA	3.79e-04	194	17	3	3526_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A	NF2 DAG1 PEG10	3.79e-04	194	17	3	3938_DN
Drug	resibufogenin	DAG1 PEG10	3.83e-04	39	17	2	CID000010063
Drug	Atractyloside potassium salt [102130-43-8]; Down 200; 5uM; PC3; HT_HG-U133A	NF2 DAG1 MAN1B1	3.85e-04	195	17	3	7393_DN
Drug	Alfaxalone [23930-19-0]; Down 200; 12uM; MCF7; HT_HG-U133A	NF2 DAG1 SCAF4	3.85e-04	195	17	3	6514_DN
Drug	Atropine-N-oxide hydrochloride [4574-60-1]; Up 200; 11.8uM; HL60; HG-U133A	MAN1B1 SCAF4 SON	3.85e-04	195	17	3	1370_UP
Drug	Canrenoic acid potassium salt [2181-04-6]; Up 200; 10uM; PC3; HT_HG-U133A	NF2 MAN1B1 MCM3AP	3.85e-04	195	17	3	7135_UP
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; MCF7; HT_HG-U133A	NF2 DAG1 MCM3AP	3.85e-04	195	17	3	4360_DN
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; PC3; HT_HG-U133A	NF2 BICRA SCAF4	3.85e-04	195	17	3	4229_DN
Drug	Selegiline hydrochloride [14611-52-0]; Down 200; 17.8uM; MCF7; HT_HG-U133A	NF2 MCM3AP SCAF4	3.85e-04	195	17	3	2826_DN
Drug	haloperidol; Down 200; 10uM; HL60; HT_HG-U133A	NF2 BICRA WASL	3.85e-04	195	17	3	1144_DN
Drug	Flecainide acetate [54143-56-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A	WASL PEG10 MCM3AP	3.85e-04	195	17	3	3843_UP
Drug	Zimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A	NF2 BICRA YLPM1	3.91e-04	196	17	3	1512_DN
Drug	Mefenamic acid [61-68-7]; Up 200; 16.6uM; PC3; HT_HG-U133A	NF2 PEG10 SCAF4	3.91e-04	196	17	3	1821_UP
Drug	Molsidomine [25717-80-0]; Up 200; 16.6uM; MCF7; HT_HG-U133A	ARID1A PEG10 FBN1	3.91e-04	196	17	3	2862_UP
Drug	Lidocaone hydrochloride [73-78-9]; Up 200; 14.8uM; HL60; HG-U133A	BICRA MAN1B1 YLPM1	3.91e-04	196	17	3	1999_UP
Drug	Edrophonium chloride [116-38-1]; Down 200; 19.8uM; HL60; HG-U133A	DAG1 MCM3AP SON	3.91e-04	196	17	3	2019_DN
Drug	Glipizide [29094-61-9]; Up 200; 9uM; MCF7; HT_HG-U133A	NF2 PRRC2A SCAF4	3.91e-04	196	17	3	1508_UP
Drug	Methyldopate hydrochloride [2508-79-4]; Down 200; 14.6uM; MCF7; HT_HG-U133A	NF2 DAG1 BICRA	3.91e-04	196	17	3	7360_DN
Drug	Benzathine benzylpenicillin [5928-84-7]; Up 200; 4.2uM; HL60; HT_HG-U133A	NF2 PEG10 YLPM1	3.91e-04	196	17	3	2939_UP
Drug	Triflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	NF2 DAG1 YLPM1	3.91e-04	196	17	3	1691_DN
Drug	Metixene hydrochloride [1553-34-0]; Up 200; 11.6uM; HL60; HT_HG-U133A	NF2 PEG10 YLPM1	3.91e-04	196	17	3	2451_UP
Drug	Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A	NF2 WASL PEG10	3.91e-04	196	17	3	6061_UP
Drug	Calciferol [50-14-6]; Up 200; 10uM; HL60; HT_HG-U133A	PEG10 APBB1IP YLPM1	3.91e-04	196	17	3	2442_UP
Drug	Ketoconazole [65277-42-1]; Down 200; 7.6uM; PC3; HT_HG-U133A	NF2 DAG1 FBN1	3.91e-04	196	17	3	4624_DN
Drug	6-mercaptopurine monohydrate; Down 200; 100uM; MCF7; HG-U133A	ARID1A NF2 MAN1B1	3.91e-04	196	17	3	334_DN
Drug	Nefopam hydrochloride [23327-57-3]; Up 200; 13.8uM; HL60; HT_HG-U133A	MAN1B1 APBB1IP MCM3AP	3.91e-04	196	17	3	2355_UP
Drug	Cotinine (-) [486-56-6]; Down 200; 22.6uM; MCF7; HT_HG-U133A	ARID1A NF2 MCM3AP	3.91e-04	196	17	3	1511_DN
Drug	Prochlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; MCF7; HT_HG-U133A	ARID1A PRRC2A SCAF4	3.97e-04	197	17	3	2641_DN
Drug	Butylparaben [94-26-8]; Up 200; 20.6uM; HL60; HT_HG-U133A	ARID1A NF2 FBN1	3.97e-04	197	17	3	3069_UP
Drug	Nafronyl oxalate [3200-06-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	NF2 DAG1 PRRC2A	3.97e-04	197	17	3	5287_DN
Drug	Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A	ARID1A NF2 SCAF4	3.97e-04	197	17	3	3748_DN
Drug	Benzydamine hydrochloride [132-69-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	PEG10 SCAF4 YLPM1	3.97e-04	197	17	3	5811_DN
Drug	phenformin hydrochloride; Up 200; 10uM; MCF7; HG-U133A	PRRC2A SON YLPM1	3.97e-04	197	17	3	21_UP
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; HL60; HT_HG-U133A	NF2 APBB1IP FBN1	3.97e-04	197	17	3	2361_UP
Drug	(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; PC3; HT_HG-U133A	ARID1A NF2 DAG1	3.97e-04	197	17	3	6663_DN
Drug	Amiprilose hydrochloride [60414-06-4]; Up 200; 11.8uM; HL60; HT_HG-U133A	NF2 PEG10 FBN1	3.97e-04	197	17	3	3000_UP
Drug	Guanethidine sulfate [60-02-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A	NF2 MCM3AP SCAF4	3.97e-04	197	17	3	3171_DN
Drug	Meticrane [1084-65-7]; Down 200; 14.6uM; PC3; HT_HG-U133A	ARID1A EZR WASL	3.97e-04	197	17	3	1792_DN
Drug	(R) -Naproxen sodium salt [26159-34-2]; Up 200; 15.8uM; MCF7; HT_HG-U133A	NF2 PEG10 MCM3AP	3.97e-04	197	17	3	6096_UP
Drug	Benserazide hydrochloride [14919-77-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A	ARID1A BICRA SCAF4	3.97e-04	197	17	3	5322_DN
Drug	Josamycin [16846-24-5]; Down 200; 4.8uM; HL60; HG-U133A	ARID1A DAG1 PRRC2A	3.97e-04	197	17	3	2034_DN
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Up 200; 25.2uM; MCF7; HT_HG-U133A	WASL PEG10 MCM3AP	3.97e-04	197	17	3	3836_UP
Drug	N6,2-O-dibutyryladenosine 3,5-cyclic monophosphate sodium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA	NF2 PRRC2A YLPM1	3.97e-04	197	17	3	959_UP
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; HL60; HT_HG-U133A	NF2 PRRC2A YLPM1	3.97e-04	197	17	3	3098_UP
Drug	Todralazine hydrochloride [3778-76-5]; Down 200; 14.8uM; PC3; HT_HG-U133A	BICRA PEG10 MCM3AP	3.97e-04	197	17	3	5087_DN
Drug	Meglumine [6284-40-8]; Down 200; 20.4uM; MCF7; HT_HG-U133A	DAG1 SCAF4 YLPM1	3.97e-04	197	17	3	5285_DN
Drug	Lysergol [602-85-7]; Down 200; 15.8uM; MCF7; HT_HG-U133A	NF2 BICRA SCAF4	3.97e-04	197	17	3	4966_DN
Drug	Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	DAG1 PRRC2A FBN1	3.97e-04	197	17	3	6288_DN
Drug	Hemicholinium bromide [312-45-8]; Down 200; 7uM; MCF7; HT_HG-U133A	NF2 BICRA MCM3AP	3.97e-04	197	17	3	3216_DN
Drug	Tomatidine [77-59-8]; Down 200; 9.6uM; MCF7; HT_HG-U133A	BICRA MCM3AP SCAF4	4.03e-04	198	17	3	2746_DN
Drug	Panthenol (D) [81-13-0]; Down 200; 19.4uM; PC3; HT_HG-U133A	BICRA SCAF4 YLPM1	4.03e-04	198	17	3	1802_DN
Drug	trifluoperazine dihydrochloride; Down 200; 10uM; PC3; HT_HG-U133A	NF2 MCM3AP SCAF4	4.03e-04	198	17	3	4448_DN
Drug	Quinic acid [86-68-0]; Down 200; 19.6uM; MCF7; HT_HG-U133A	ARID1A NF2 SCAF4	4.03e-04	198	17	3	3540_DN
Drug	Flecainide acetate [54143-56-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	NF2 BICRA SCAF4	4.03e-04	198	17	3	3418_DN
Drug	Sulfaguanidine [57-67-0]; Down 200; 18.6uM; PC3; HG-U133A	ARID1A PEG10 SON	4.03e-04	198	17	3	1913_DN
Drug	Ketotifen fumarate [34580-14-8]; Down 200; 9.4uM; HL60; HG-U133A	DAG1 MCM3AP SCAF4	4.03e-04	198	17	3	1583_DN
Drug	troglitazone; Down 200; 10uM; SKMEL5; HG-U133A	NF2 EZR MAN1B1	4.03e-04	198	17	3	504_DN
Drug	AG-028671 [847803-03-6]; Down 200; 10uM; MCF7; HT_HG-U133A	NF2 BICRA SCAF4	4.03e-04	198	17	3	6587_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	NF2 MCM3AP YLPM1	4.03e-04	198	17	3	7003_DN
Disease	feeling "fed-up" measurement	DAG1 YLPM1	8.68e-04	76	17	2	EFO_0009588

Protein segments in the cluster

Peptide	Gene	Start	Entry
MEPPPDFVPPPPPSY	APBB1IP	576	Q7Z5R6
VPPMTRPPPSNYQPP	ARID1A	1561	O14497
SVQPEPPPPEPVPMY	MCM3AP	1061	O60318
PPYQPPPPFTAPMEG	DAG1	861	Q14118
MYSPIPPSLPPPAPQ	PEG10	476	Q86TG7
VATTVVMYPPPPPPP	MAN1B1	31	Q9UKM7
YPPMNPIPAPLPPDI	NF2	481	P35240
VPMVIPGRPEYPPPP	FBN1	391	P35555
VMTAPPPPPPPVYEP	EZR	466	P15311
EPAAPPPPPPRTFQM	BICRA	931	Q9NZM4
FPPMAQPVIPPTPPV	SCAF4	376	O95104
YMTDLQRPQPPPPPP	SYN1	21	P17600
MGVPPPPPPAPDYVL	NR5A1	126	Q13285
MRSETPPVPPPPPYL	PRRC2A	821	P48634
MPPPFVPYSQMPPPL	YLPM1	516	P49750
VPYSQMPPPLPTMPP	YLPM1	521	P49750
SVAVPPPPPNRMYPP	WASL	331	O00401
TEAYMVPPLPPEEPP	SON	1141	P18583